Lac-Hydrin - Ranbaxy, Inc

Manufacturer
Ranbaxy, Inc
Effective date
2008-01-28
Label type
HUMAN PRESCRIPTION DRUG LABELING
Version
1
Source
full-release
Hydrated at
2026-05-31 20:07:05

Label at a glance#

ProductLac-Hydrin
Label structure11 sections

Indications and uses

Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.

Dosage and administration

Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For Dermatologic use only. Not for Ophthalmic, Oral or Intravaginal use.

DESCRIPTION

DESCRIPTION SECTION

Lac-Hydrin specially formulates 12% lactic acid, neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.4-5.5. Lac-Hydrin (ammonium lactate) Lotion 12% also contains cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methyl- and propyl parabens, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol and water. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula:DESCRIPTIONDESCRIPTION

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known.

An in vitro study of percutaneous absorption of Lac-Hydrin Lotion using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.

INDICATIONS AND USAGE

INDICATIONS AND USAGE SECTION

Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Lac-Hydrin Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

WARNING

WARNINGS SECTION

Sun exposure to areas of the skin treated with Lac-Hydrin (ammonium lactate) Lotion, 12% should be minimized or avoided (see PRECAUTIONS). The use of Lac-Hydrin Lotion should be discontinued if any hypersensitivity is observed.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.

Information For Patients

INFORMATION FOR PATIENTS SECTION

Patients using Lac-Hydrin (ammonium lactate) Lotion, 12% should receive the following information and instructions:

  1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only. Avoid contact with eyes, lips, or mucous membranes.
  2. Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin.
  3. This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs).
  4. If the skin condition worsens with treatment, the medication should be promptly discontinued

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION

The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation.

The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative.

In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or post-natal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m2/day), approximately 0.4 times the human topical dose.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects: Pregnancy Category B.

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m2/day in the rat and 7200 mg/m2/day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Lac-Hydrin Lotion should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lac-Hydrin is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of Lac-Hydrin have been demonstrated in infants and children. No unusual toxic effects were reported.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of Lac-Hydrin (ammonium lactate) Lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse experiences in patients with xeroxis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation.

Due to more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).

OVERDOSAGE

The oral administration of Lac-Hydrin to rats and mice showed this drug to be practically non-toxic (LD50 > 15 mL/kg).

DOSAGE AND ADMINISTRATION

DOSAGE AND ADMINISTRATION SECTION

Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lac-Hydrin® (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.

Store at controlled room temperature 15° C - 30° C (59° F - 86° F).

Manufactured for:

Bristol-Myers Squibb Co

Princeton, NJ 08543 USA

By: Contract Pharmaceuticals Limited Niagara

Buffalo, NY 14213 USA

Revised January 2008

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197362ammonium lactate 12 % Topical LotionPSN1
543812Lac-Hydrin 12 12 % Topical LotionPSN1
543812ammonium lactate 120 MG/ML Topical Lotion [Lac-Hydrin]SBD1
197362ammonium lactate 120 MG/ML Topical LotionSCD1
197362ammonium lactate 12 % Topical LotionSY1
197362ammonium lactate 120 MG/ML (as neutralized lactic acid 12 % ) Topical LotionSY1
543812Lac-Hydrin 12 12 % Topical LotionSY1
543812Lac-Hydrin 12 120 MG/ML Topical LotionSY1
543812Lac-Hydrin 12 Topical LotionSY1

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0072-5712-08Lac-Hydrin225 g in 1 BOTTLE, PLASTICLOTION2251
0072-5712-14Lac-Hydrin400 g in 1 BOTTLE, PLASTICLOTION4001

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0072-5712LAC-HYDRIN (AMMONIUM LACTATE) LOTION [RANBAXY, INC]12 package rows20080205_3d94a218-ae4d-4158-bd8e-92743c7c8e0d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0072-5712-08GM - Gram0072-5712d6b7e3da-2520-4366-b1e2-75600fdfbd9012013-02-13
0072-5712-14GM - Gram0072-571255c75d67-c0f1-42ad-b9ac-29543c5cfb8812013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ammonium lactateACTIVE INGREDIENT67M901L9NQ1
lactic acid, DL-ACTIVE MOIETY3B8D35Y7S41
cetyl alcoholINACTIVE INGREDIENT936JST6JCN1
fraganceINACTIVE INGREDIENT1
glycerinINACTIVE INGREDIENTPDC6A3C0OX1
glyceryl stearateINACTIVE INGREDIENT230OU9XXE41
laureth-4INACTIVE INGREDIENT1
light mineral oilINACTIVE INGREDIENT1
magnesium aluminum silicateINACTIVE INGREDIENT1
methyl and propyl parabensINACTIVE INGREDIENT1
methylcelluloseINACTIVE INGREDIENT1
PEG-100 stearateINACTIVE INGREDIENT1
polyoxyl 40 stearateINACTIVE INGREDIENT1
propylene glycolINACTIVE INGREDIENT6DC9Q167V31
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0072-57120072-5712-08, 0072-5712-14

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 5 · 261 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
light mineral oilLIGHT MINERAL OILN6K5787QVPPASTE / DENTAL687 mgName fallback — name candidate
19 equally ranked IID candidates
cetyl alcoholCETYL ALCOHOL936JST6JCNAEROSOL, FOAM / RECTAL17 mgExact identifier — unii candidate
20 equally ranked IID candidates
cetyl alcoholCETYL ALCOHOL936JST6JCNSUSPENSION / AURICULAR (OTIC)1 %w/vExact identifier — unii candidate
20 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSPRAY, METERED / NASAL13 mgExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXINJECTION, SOLUTION / INTRAVENOUS15 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3ELIXIR / ORAL9306 mgExact identifier — unii candidate
81 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HPOWDER, FOR SUSPENSION / ORAL59.5 mg/5mlName fallback — name candidate
24 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HTABLET, COATED / ORAL138.3 mgName fallback — name candidate
24 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL / VAGINAL750 mgExact identifier — unii candidate
81 equally ranked IID candidates
glyceryl stearateGLYCERYL MONOSTEARATE230OU9XXE4CREAM / TOPICAL836 mgExact identifier — unii candidate
21 equally ranked IID candidates
cetyl alcoholCETYL ALCOHOL936JST6JCNSUSPENSION / OPHTHALMIC0.5 %w/vExact identifier — unii candidate
20 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / ORAL27120 mgExact identifier — unii candidate
81 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXINJECTION, SOLUTION / INTRAMUSCULAR15 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXJELLY / VAGINALNAExact identifier — unii candidate
75 equally ranked IID candidates
glyceryl stearateGLYCERYL MONOSTEARATE230OU9XXE4CAPSULE, EXTENDED RELEASE / ORAL32.4 mgExact identifier — unii candidate
21 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HINJECTION / INTRAMUSCULAR0.1 %w/vName fallback — name candidate
24 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSHAMPOO / TOPICAL5 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
light mineral oilLIGHT MINERAL OILN6K5787QVPCREAM / TOPICAL456 mgName fallback — name candidate
19 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3LIQUID / ORAL29008 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL / OPHTHALMIC0.44 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAMUSCULAR4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii candidate
81 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXCREAM / VAGINAL60 mgExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3EMULSION / TOPICAL8 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
glyceryl stearateGLYCERYL MONOSTEARATE230OU9XXE4SUSPENSION / OPHTHALMIC0.5 %w/vExact identifier — unii candidate
21 equally ranked IID candidates
light mineral oilLIGHT MINERAL OILN6K5787QVPCREAM, AUGMENTED / TOPICAL25 %w/wName fallback — name candidate
19 equally ranked IID candidates
light mineral oilLIGHT MINERAL OILN6K5787QVPGEL / TOPICAL20 mgName fallback — name candidate
19 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXLIQUID / ORAL2400 mgExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSOAP / TOPICAL0.76 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXFILM, EXTENDED RELEASE / TRANSDERMAL306.2 mgExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSOLUTION / RESPIRATORY (INHALATION)5 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HCREAM / TOPICAL1.3 %w/wName fallback — name candidate
24 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXINJECTION, SUSPENSION / SUBCUTANEOUS1.6 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL / TOPICAL4522 mgExact identifier — unii candidate
81 equally ranked IID candidates
magnesium aluminum silicateMAGNESIUM ALUMINUM SILICATE6M3P64V0NCTABLET, CHEWABLE / ORAL12 mgName fallback — name candidate
17 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / OPHTHALMIC0.6 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / TOPICAL4974 mgExact identifier — unii candidate
81 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HTABLET / SUBLINGUAL4 mgName fallback — name candidate
24 equally ranked IID candidates
laureth-4LAURETH-46HQ855798JSOLUTION / TOPICAL5.22 %w/vName fallback — name candidate
4 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXINJECTION / INTRAVENOUS33750 mgExact identifier — unii candidate
75 equally ranked IID candidates
glyceryl stearateGLYCERYL MONOSTEARATE230OU9XXE4CREAM / VAGINAL140 mgExact identifier — unii candidate
21 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SHAMPOO, SUSPENSION / TOPICAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXCREAM / TOPICAL1800 mgExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3FILM, SOLUBLE / BUCCAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HTABLET, CHEWABLE / ORAL50 mgName fallback — name candidate
24 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / AURICULAR (OTIC)10 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / SUBCUTANEOUS1.4 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
magnesium aluminum silicateMAGNESIUM ALUMINUM SILICATE6M3P64V0NCSUSPENSION / ORAL5000 mg/5mlName fallback — name candidate
17 equally ranked IID candidates
methylcelluloseMETHYLCELLULOSEZ944H5SN0HSYRUP / ORALNAName fallback — name candidate
24 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSOLUTION / AURICULAR (OTIC)63.64 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM / VAGINAL1225 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / RECTAL1214 mgExact identifier — unii candidate
81 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXMOUTHWASH / BUCCAL100 mg/1mlExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSPONGE / TOPICAL2 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSUSPENSION/ DROPS / OPHTHALMIC2.5 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
cetyl alcoholCETYL ALCOHOL936JST6JCNEMULSION / TOPICALNAExact identifier — unii candidate
20 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3PASTE / DENTAL0.5 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CLOTH / TOPICAL0.03 mg/mgExact identifier — unii candidate
81 equally ranked IID candidates
glycerinGLYCERINPDC6A3C0OXSUSPENSION / ORAL26208 mgExact identifier — unii candidate
75 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
10EDCA6F-2132-E59C-81C5-65E4D5623D143d94a218-ae4d-4158-bd8e-92743c7c8e0d2008-01-28Warnings, Adverse reactionsExact identifier
spl id: 10EDCA6F-2132-E59C-81C5-65E4D5623D14
spl set id: 3d94a218-ae4d-4158-bd8e-92743c7c8e0d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.